Abstract
Introduction: In this single-center study of 268 acute myeloid leukemia (AML) patients, we have tested if a subset of 4 routinely employed immunophenotypic stem cell-associated markers correlated with the presence of recurrently mutated genes and if the markers were predictive for mutational status. Methods: Immunophenotypic data from 268 diagnostic AML samples obtained in 2009–2018 were analyzed retrospectively for the antigens CD34, CD117, CD123, and CLEC12A. Correlation between immunophenotypes and mutations was analyzed by Fischer’s exact test. Clinical applicability of the markers for predicting mutational status was evaluated by receiver operating characteristics analyses, where an area under the curve (AUC) of at least 0.85 was accepted as clinically relevant. Results: For a number of genes, the antigen expression differed significantly between mutated and wild-type gene expression. Despite low AUCs, CD123 and CLEC12A correlated with FLT3+NPM1− and FLT3+NPM1+. Three subsets met the AUC requirements (CD34+, CD34+CD117+, and CD34−CD117+) for predicting FLT3−NPM1+ or FLT3+NPM1+. Conclusion: The value of immunophenotypes as surrogate markers for mutational status in AML seems limited when employing CD123 and CLEC12A in combination with CD34 and CD117. Defining relevant cutoffs for given markers is challenging and hampered by variation between laboratories and patient groups.
References
1.
Larrosa-Garcia
M
, Baer
MR
. FLT3 inhibitors in acute myeloid leukemia: current status and future directions
. Mol Cancer Ther
. 2017
;16
(6
):991
–1001
. .2.
Nassereddine
S
, Lap
CJ
, Haroun
F
, Tabbara
I
. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
. Ann Hematol
. 2017
;96
(12
):1983
–91
. .3.
Nassereddine
S
, Lap
CJ
, Tabbara
IA
. Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy
. Onco Targets Ther
. 2019
;12
:303
–8
. .4.
Dohner
H
, Weisdorf
DJ
, Bloomfield
CD
. Acute myeloid leukemia
. N Engl J Med
. 2015
;373
(12
):1136
–52
.5.
Dombret
H
, Gardin
C
. An update of current treatments for adult acute myeloid leukemia
. Blood
. 2016
;127
(1
):53
–61
. .6.
Dohner
H
, Estey
E
, Grimwade
D
, Amadori
S
, Appelbaum
FR
, Buchner
T
, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
. Blood
. 2017
;129
(4
):424
–47
.7.
Port
M
, Böttcher
M
, Thol
F
, Ganser
A
, Schlenk
R
, Wasem
J
, et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis
. Ann Hematol
. 2014
;93
(8
):1279
–86
. .8.
Im
AP
, Sehgal
AR
, Carroll
MP
, Smith
BD
, Tefferi
A
, Johnson
DE
, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
. Leukemia
. 2014
;28
(9
):1774
–83
. .9.
Schuurhuis
GJ
, Heuser
M
, Freeman
S
, Béné
MC
, Buccisano
F
, Cloos
J
, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
. Blood
. 2018
;131
(12
):1275
–91
. .10.
Platzbecker
U
, Middeke
JM
, Sockel
K
, Herbst
R
, Wolf
D
, Baldus
CD
, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
. Lancet Oncol
. 2018
;19
(12
):1668
–79
. .11.
Junca
J
, Garcia-Caro
M
, Granada
I
, Rodriguez-Hernandez
I
, Torrent
A
, Morgades
M
, et al. Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis
. Ann Hematol
. 2014
;93
(9
):1483
–9
.12.
Guo
RJ
, Atenafu
EG
, Schimmer
AD
, Minden
MD
, Chang
H
. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia
. Int J Lab Hematol
. 2017
;39
(4
):429
–37
. .13.
Zeijlemaker
W
, Kelder
A
, Wouters
R
, Valk
PJM
, Witte
BI
, Cloos
J
, et al. Absence of leukaemic CD34+ cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered
. Br J Haematol
. 2015
;171
(2
):227
–38
.14.
Baqai
J
, Crisan
D
. Correlation of FLT3 mutations with expression of CD7 in acute myeloid leukemia
. Appl Immunohistochem Mol Morphol
. 2015
;23
(2
):104
–8
. .15.
Terwijn
M
, Feller
N
, van Rhenen
A
, Kelder
A
, Westra
G
, Zweegman
S
, et al. Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML
. Eur J Cancer
. 2009
;45
(9
):1692
–9
. .16.
Ossenkoppele
GJ
, van de Loosdrecht
AA
, Schuurhuis
GJ
. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms
. Br J Haematol
. 2011
;153
(4
):421
–36
. .17.
Chen
X
, Wood
BL
. Monitoring minimal residual disease in acute leukemia: technical challenges and interpretive complexities
. Blood Rev
. 2017
;31
(2
):63
–75
. .18.
Bakker
AB
, van den Oudenrijn
S
, Bakker
AQ
, Feller
N
, van Meijer
M
, Bia
JA
, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia
. Cancer Res
. 2004
;64
(22
):8443
–50
. .19.
Larsen
HØ
, Roug
AS
, Just
T
, Brown
GD
, Hokland
P
. Expression of the hMICL in acute myeloid leukemia: a highly reliable disease marker at diagnosis and during follow-up
. Cytometry B Clin Cytom
. 2012
;82
(1
):3
–8
. .20.
Testa
U
, Pelosi
E
, Frankel
A
. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
. Biomark Res
. 2014
;2
(1
):4
. .21.
Bras
AE
, de Haas
V
, van Stigt
A
, Jongen-Lavrencic
M
, Beverloo
HB
, Te Marvelde
JG
, et al. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping
. Cytometry B Clin Cytom
. 2019
;96
(2
):134
–42
. .22.
Ehninger
A
, Kramer
M
, Röllig
C
, Thiede
C
, Bornhäuser
M
, von Bonin
M
, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
. Blood Cancer J
. 2014
;4
:e218
. .23.
Angelini
DF
, Ottone
T
, Guerrera
G
, Lavorgna
S
, Cittadini
M
, Buccisano
F
, et al. A leukemia-associated CD34/CD123/CD25/CD99+ immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia
. Clin Cancer Res
. 2015
;21
(17
):3977
–85
. .24.
Heo
SK
, Noh
EK
, Kim
JY
, Jeong
YK
, Jo
JC
, Choi
Y
, et al. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death
. Sci Rep
. 2017
;7
(1
):15278
. .25.
Ostgard
LS
, Norgaard
JM
, Severinsen
MT
, Sengelov
H
, Friis
L
, Jensen
MK
, et al. Data quality in the Danish National Acute Leukemia Registry: a hematological data resource
. Clin Epidemiol
. 2013
;5
:335
–44
.26.
R: A Language and Environment for Statistical Computing. 2019. Available from: http://www.R-project.org/
.27.
Ostgard
LS
, Norgaard
JM
, Sengelov
H
, Severinsen
M
, Friis
LS
, Marcher
CW
, et al. Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study
. Leukemia
. 2015
;29
(3
):548
–55
.28.
Grimwade
D
, Hills
RK
, Moorman
AV
, Walker
H
, Chatters
S
, Goldstone
AH
, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5,876 younger adult patients treated in the United Kingdom Medical Research Council trials
. Blood
. 2010
;116
(3
):354
–65
. .29.
Wang
YY
, Chen
WL
, Weng
XQ
, Sheng
Y
, Wu
J
, Hao
J
, et al. Low CLL-1 expression is a novel adverse predictor in 123 patients with De Novo CD34+ acute myeloid leukemia
. Stem Cells Dev
. 2017
;26
(20
):1460
–7
.30.
Paietta
E
. Consensus on MRD in AML?
Blood
. 2018
;131
(12
):1265
–6
. .© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
